No quarterly revenue total was found in Dogwood Therapeutics, Inc.'s SEC filings.
Dogwood Therapeutics, Inc. (DWTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $9.6 million in cash and investments and $127,208 in total debt.
Revenue
—
Net income
$-11.53M
-202.8% vs year-ago quarter
Operating cash flow
$-3.61M
+10.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.34
+82.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
33.99M
+1678.7% vs year-ago quarter
Net cash
$9.48M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DWTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Alpharetta, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1818844
- Former names
- Virios Therapeutics, Inc. (until Oct 15, 2024); Virios Therapeutics, LLC (until Dec 16, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$14.1M | -$5.1M | -$3.8M | -$15.8M | -$3.9M |
| Net income | -$11.5M | -$5.0M | -$3.8M | -$15.7M | -$3.8M |
| Diluted EPS | -$0.34 | -$0.15 | -$0.26 | -$8.20 | -$1.99 |
| Operating cash flow | -$3.6M | -$4.6M | -$3.6M | -$3.3M | -$4.0M |
| Total assets | $80.5M | $95.2M | $90.2M | $92.0M | $96.7M |
| Total liabilities | $12.1M | $14.6M | $15.3M | $14.6M | $14.2M |
| Stockholders' equity | $68.4M | $80.6M | $74.9M | $7.3M | $6.9M |
| Cash and investments | $9.6M | $13.2M | $6.5M | $10.1M | $13.4M |
| Total debt | $127,208 | $144,930 | $162,604 | $174,778 | $186,990 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 17, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
All 328 Dogwood Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.